Sponsors / EXEL
EXEL

Exelixis

Company identity has not yet been verified

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
14Trials in this database
17Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Study of XL184 (Cabozantinib) in Adults With Glioblastoma MultiformeNCT00704288ExelixisPhase 2Completed2012-06Actual
Study of Cabozantinib (XL184) in Adults With Advanced MalignanciesNCT00940225ExelixisPhase 2Completed2013-05Actual
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second RelapseNCT01068782ExelixisPhase 2Terminated2011-05Actual
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCNCT01995058ExelixisPhase 2Terminated2014-11Actual
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyNCT03690388ExelixisPhase 3Active not recruiting2020-08-19Actual
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyNCT03755791ExelixisPhase 3Active not recruiting2021-11-30Actual
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03937219ExelixisPhase 3Active not recruiting2022-01-31Actual
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117ExelixisPhase 3Active not recruiting2024-04-19Actual
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerNCT05425940ExelixisPhase 3Active not recruiting2026-06-16Actual
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNCT05678673ExelixisPhase 3Active not recruiting2026-12-15Estimated
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06082167ExelixisPhase 2, Phase 3Active not recruiting2028-08Estimated
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsNCT06943755ExelixisPhase 2, Phase 3Recruiting2029-06-30Estimated
A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaNCT07428616ExelixisPhase 2Recruiting2028-02-29Estimated
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574ExelixisPhase 3Enrolling by invitation2030-05-31Estimated

Latest recorded trial changes

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

NCT01068782 · Exelixis

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: In the Randomized Phase, to evaluate the preliminary efficacy and tolerability of multiple regimens of XL184; measure: In the Expansion Phase, to evaluate the efficacy of XL184 treatment

+ Updated value

measure: Randomized Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs); measure: Expansion Phase: Objective Response Rate (ORR)

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117 · Exelixis

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Duration of Progression Free Survival per Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1); measure: Duration of Overall Survival (OS)

+ Updated value

measure: Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC); measure: Duration of Overall Survival (OS)

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

NCT03755791 · Exelixis

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Duration of Progression Free Survival (PFS) for the experimental arm vs. the control arm; measure: Duration of Overall Survival (OS) for the experimental arm vs. the control arm

+ Updated value

measure: Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population; measure: Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

NCT05425940 · Exelixis

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Overall Survival

+ Updated value

measure: Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized Participants; measure: Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in Randomized Non-Liver Metastases (NLM) Participants

Check registry source · The saved outcome text may be shortened. Check the source for full wording.